INZY Inozyme Pharma, Inc.: institutional ownership and insider trading
1 funds reported holding $693K of Inozyme Pharma, Inc. in their latest 13F filings; in Q3 2025 funds net bought $0, with 0 new positions and 85 funds selling out; over the last 12 months insiders bought $0 and sold $0 on the open market.
INZY revenue and earnings
- Quarter ended Mar 31, 2025: revenue n/a, net income −$28.0M, EPS -0.44
- Quarter ended Dec 31, 2024: revenue n/a, net income −$27.1M, EPS -0.41
- Quarter ended Sep 30, 2024: revenue n/a, net income −$24.6M, EPS -0.39
- Quarter ended Jun 30, 2024: revenue n/a, net income −$27.0M, EPS -0.44
Largest institutional holders of INZY
- Nuveen Asset Management, LLC — $693K
Recent INZY insider trades
- Apr 2, 2025: Treco Douglas A sold 8,819 shares ($7.85K)
5%+ owners
- Glazer Capital, LLC: 6.6% (Schedule 13G, filed Jun 4, 2025)
Who owns the most INZY stock?
The largest institutional holders of Inozyme Pharma, Inc. in the latest 13F filings are Nuveen Asset Management, LLC ($693K).
Are insiders buying or selling INZY?
No open-market insider buys or sells of Inozyme Pharma, Inc. were reported in the last 12 months.